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Abstract 
S100B is a small Ca2+ binding protein member of S100 family. Within the central 
nervous system, S100B is mostly expressed by astrocytes, though it has been shown 
to be also expressed by oligodendrocytes, microglia and some neural populations. 
S100B exerts both intracellular and extracellular functions. Within cells S100B acts as 
a signaling molecule, being involved in the regulation of energy metabolism and in the 
modulation of both proliferation and differentiation of neurons and glia. When secreted 
to the extracellular space, S100B exerts beneficial or detrimental effects in a 
concentration-dependent manner: (i) nanomolar concentrations have been reported to 
exert trophic effects whereas (ii) micromolar concentrations have shown to produce 
neurodegenerative, neuroinflammatory and/or apoptotic outcomes. Multiple sclerosis 
(MS) is an autoimmune chronic inflammatory disease with a neurodegenerative 
component, characterized by the occurrence of focal areas of inflammatory 
demyelination, variable gliosis and relative axonal loss, with limited remyelination. 
Moreover, data from previous research of other authors and from ongoing work of our 
group have shown augmented S100B in both CSF, serum and post-mortem plaques of 
MS patients.  
With this work we intended to explore the role of S100B in MS main mechanisms. 
For this end we used mouse cerebellar organotypic slice cultures, a previously 
described model of demyelination. Therefore, we first evaluated the expression and 
secretion of S100B in the course of a demyelinating insult. Our results reveal that 
S100B is released and overexpressed upon demyelination mainly by astrocytes. Next, 
we also evaluated in what way S100B might affect demyelination, reactivity of glial cells 
and inflammatory response in consequence of demyelination, by blocking extracellular 
S100B with a specific antibody. Upon the demyelination insult, we verified an 
upregulation of myelin proteins and pro-inflammatory cytokines gene expression, as 
well as activation of astrocytes and microglia. In turn, blockade of S100B appeared to 
prevent demyelination and reduce both reactive gliosis and expression of pro-
inflammatory factors. Altogether, these data strongly suggest that high levels of S100B 
may exacerbate demyelination and/or delay remyelination.  
Keywords: S100B, Multiple Sclerosis, demyelination, inflammatory response
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Resumo 
A S100B é uma proteína de ligação ao Ca2+ da super-família de proteínas S100. 
No Sistema Nervoso Central a S100B é maioritariamente expressa pelos astrócitos, 
apesar de haver evidência da sua expressão em oligodendrocitos, microglia e certas 
populações de neurónios. Sabe-se que o S100B pode ter diferentes funções, 
consoante a sua localização: intracelular ou extracelular. Quando expresso 
intracelularmente actua como uma molécula sinalizadora, estando envolvido em 
processos de regulação do metabolismo energético, bem como na proliferação e 
diferenciação neuronal e das células gliais. Uma vez secretado para o espaço 
extracelular, o S100B pode exercer efeitos benéficos ou prejudiciais nas células 
cerebrais, dependendo da sua concentração: (i) enquanto que concentrações 
fisiológicas na ordem dos nanomolar tem efeitos tróficos, (ii) concentrações mais 
elevadas, da ordem dos micromolar, induzem a neurodegeneração, neuroinflamação e 
apoptose destas células. A Esclerose Múltipla (EM) é uma doença autoimune crónica 
inflamatória com uma grande componente neurodegenerativa. Patologicamente, a EM 
é caracterizada pela ocorrência de focos de desmielinização e inflamação, 
reactividade das células gliais e disfunção neuronal, podendo haver alguma 
remielinização. Dados de pesquisa publicados por outros autores e dados preliminares 
do nosso grupo demonstram a presença de níveis anormais de S100B em amostras 
de líquido cefalo-raquidiano, soro e placas escleróticas de doentes de EM.  
Com este trabalho pretendemos investigar o papel da proteína S100B nos 
principais mecanismos que levam ao desenvolvimento da EM. Para tal, recorremos a 
um modelo de culturas organotipicas de cerebelo de ratinho, um modelo já usado para 
estudos de mielinização e desmielinização. Começámos por avaliar os níveis de 
expressão e secreção de S100B no decurso da desmielinização. De acordo com os 
resultados obtidos, verificou-se uma sobre-expressão e aumento de secreção de 
S100B, em resposta ao insulto desmielinizante, mediada maioritariamente pelos 
astrócitos. Seguidamente decidimos também verificar de que modo o S100B poderá 
estar a afectar a desmielinização e a reactividade das células gliais e a resposta 
inflamatória, através do bloqueio extracelular de S100B com um anticorpo especifico 
para a proteína. Após a desmielinização, observou-se uma marcada desmielinização 
associada a uma sobre-expressão de genes que regulam as proteínas da mielina e de 
certas citocinas pro-inflamatórias, bem como a activação dos astrócitos e micróglia. 
Por sua vez, o bloqueio do S100B extracelular mostrou ter um efeito preventivo da 
desmielinização bem como atenuante da reactividade glial e da expressão de citocinas 
 x 
 
pró-inflamatórias. Estes resultados permitem-nos inferir que níveis elevados de S100B 
podem favorecer a desmielinização e/ou retardar a remielinização.  
 
 
Palavras chave: S100B, Esclerose Múltipla, desmielinização, resposta inflamatória
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Introduction 
S100B 
S100 proteins consist in one of the largest family of small proteins involved in 
calcium ion (Ca2+) homeostasis. Members of the S100 protein family are known to 
contain two EF-hand helix-loop-helix Ca2+ binding domains: a canonical C-terminal and 
a non-canonical N-terminal (Kawasaki et al., 1998). Ca2+ binds to these domains 
causing conformational changes, exposing a hydrophobic cleft, which is required for 
interaction with target proteins and their modulation (Yap et al., 1999; Zimmer and 
Weber, 2010).  
S100A1 and S100B were the first members of S100 family to be identified as 
components of the S100 protein fraction that was extracted from bovine brain, this 
fraction presented homodimers and heterodimers of both proteins (Moore, 1965; Moore 
et al., 1968). S100B is expressed by a restrict number of cell types from different 
organs and tissues, although it appears to be abundantly expressed by central and 
peripheral nervous system glial cells (Donato, 2003; Rambotti et al., 1989). In these 
cells S100B may be observed both in a soluble form diffusely in the cytoplasm or 
associated with intracellular membranes, centrosomes, microtubules and type III 
intermediate filaments (Donato, 2003, 2007). 
1.1. S100B double life 
As most S100 proteins, S100B exists within cells as antiparallel homodimers, with 
the two subunits held together by non-covalent disulfide bonds (Donato, 2001; 
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Heizmann, 2002) or as an heterocomplex in association with S100A1 monomer (Isobe 
et al., 1983).  
Recent studies have shown that S100B monomers have the ability to assemble 
into more complex oligomers, such as tetramers, hexamers and octamers, and that 
both the degree of oligomerization and the type of bond that holds the monomers might 
be related to its function (Donato, 2007). Dimeric forms of S100B are mainly associated 
with intracellular roles, such as modulation of microtubule assembly and regulation of 
cell cycle by interaction with transcription factors in a Ca2+-dependent manner (Davey 
et al., 2001). Therefore, changes in intracellular Ca2+ concentrations cause S100B 
secretion to the extracellular space where it is known to exert cytokine-like functions 
(Davey et al., 2001). Such functions require specific binding to cell receptors such as 
the receptor for advanced glycation end products (RAGE), to which S100B binds 
preferentially when in tetrameric/octameric forms promoting RAGE dimerization 
(Ostendorp et al., 2007).  
RAGE receptor is a member of the immunoglobulin-like cell surface receptor super 
family that is primarily involved in inflammation, nephropathy, neurodegeneration, and 
cancer. It is composed by an extracellular moiety, with one N-terminal V-type and two 
C-type Ig domains, a single transmembrane spanning helix and a short cytosolic 
domain, which is necessary for signal transduction (Neeper et al., 1992; Rauvala and 
Rouhiainen, 2010; Soroka et al., 2003). The outcome of S100B binding to RAGE 
depends on the extracellular levels of the ligand: nanomolar (nM) concentrations of 
S100B were shown to exert neurotrophic and neuroprotective functions at neuronal 
level, promoting neurite growth and neuronal survival (Barger et al., 1995; Kögel et al., 
2004); and micromolar (µM) concentrations have been shown to accomplish opposite 
effects, activating a pro-apoptotic pathways (Van Eldik and Wainwright, 2003; Huttunen 
et al., 2000). Recent studies have shown that extracellular S100B does not operate 
solely via RAGE binding. It was suggested that in proliferating myoblasts S100B binds 
to the cell fibroblast growth factor (FGF) receptor 1 (FGFR1) trough interaction with 
basic FGF (bFGF) (Riuzzi et al., 2011). This engagement results in the recruitment of 
RAGE into a RAGE/S100B/bFGF/FGFR tetracomplex, which in turn will enhance the 
Role of S100B on Central Nervous System Demyelination and Remyelination 
3 
mitogenic signaling pathway activated by bFGF-FGFR1 assembling and inactivate 
RAGE signaling, promoting skeletal muscle regeneration (Riuzzi et al., 2012; Sorci et 
al., 2013).   
As previously mentioned, within cells S100B might act as an intracellular regulator. 
Indeed, upon Ca2+ binding S100B dimmers suffer a conformational change exposing 
the hydrophobic residues, and consequently creating a hydrophobic cleft through which 
S100B can bind to target proteins (Iuvone et al., 2007). Many target proteins of S100B 
have been identified, involving S100B in diverse intracellular events as regulation of 
Ca2+ homeostasis, cell proliferation and differentiation, protein phosphorylation, 
enzyme and channel activities, protein degradation, assembly of several cytoskeleton 
components, cell locomotion, dark adaptation of photoreceptors and the innate 
inflammatory response (Table I. 1). It is quite clearly that S100B plays a protective role 
as long as it is kept within the cells at physiological levels.  
Within the Central Nervous System (CNS), S100B is known to be actively secreted 
by astrocytes, which is believed to occur through activation of metabotropic glutamate 
receptor 3 (mGluR3) in a neural and synaptic activity dependent manner (Sakatani et 
al., 2008; Shashoua et al., 1984). Once in the extracellular space S100B exerts 
beneficial or detrimental effects on neurons, microglia and astrocytes depending on the 
concentration (Van Eldik and Wainwright, 2003). At physiological concentrations 
around nM levels S100B behaves as a signaling trophic protein promoting neuronal 
survival, astrocytic proliferation and microglia quiescence (Gonçalves et al., 2000; Reali 
et al., 2005; Selinfreund et al., 1991; Zhang et al., 2011b). 
When S100B levels rise to the range of µM the whole scenario is reversed with 
production of reactive species of oxygen (ROS) leading to neuronal death. Moreover, 
inflammatory activities of astrocytes are potentiated and microglia is activated as 
evidenced by the expression and release of pro-inflammatory cytokines (Adami et al., 
2001; Businaro et al., 2006; Petrova et al., 2000). Several studies have shown that 
both trophic and toxic effects of extracellular S100B are mediated by its binding to 
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RAGE and might depend on the intensity and extent of activation of the receptor, as 
well as on its level of expression in CNS cells (Donato, 2007).  
Table I. 1 – S100B intracellular main target proteins and respective functions. 
Cell Function Target Protein/ Pathways Reference 
Cell proliferation and 
differentiation 
p53 
IKKβ/NF-B 
PI3-K/Akt/p21WAF1/cdk4/Rb/E2F 
(Lin et al., 2004) 
(Tubaro et al., 2011) 
(Arcuri et al., 2005) 
Receptor function D2 receptor/ERK1/2/adenyl cyclase (Liu et al., 2008) 
Protein 
phosphorylation 
 proteins 
GAP43 
p80 
p53 
GFAP and vimentin 
(Baudier and Cole, 1988) 
(Sheu et al., 1994) 
(Pozdnyakov et al., 1998) 
(Baudier et al., 1992) 
(Ziegler et al., 1998) 
Ca2+ homeostasis AHNAK 
Annexin 6 
(Gentil et al., 2001) 
(Marisa et al., 1998) 
Protein degradation E3 ligase hdm2 (Wilder et al., 2006) 
Cell locomotion Src/PI3-K/RhoA/ROCK and 
Src/PI3-K/Akt/Gsk3β/Rac1 
(Brozzi et al., 2009) 
Enzyme activity Membrane bound GC 
Fructose-1,6-bisphospate aldolase 
(Rambotti et al., 1999) 
(Zimmer & Van Eldik, 1986) 
Cytoskeleton 
assembly 
Microtubules 
Type III intermediate filaments 
Caldesmon 
Calponin 
IQGAP1 
(Donato, 1984) 
(Garbuglia et al., 1999) 
(Polyakov et al., 1998) 
(Fujii et al., 1994) 
(Mbele et al., 2002) 
Transcription 
regulation 
p53 (Lin et al., 2001) 
Channel activity EAG1 K+ (Sahoo et al., 2010) 
Nevertheless, although having been extensively studied over the past five 
decades, there is no evidence of accordance between intracellular regulatory activities 
of S100B and its extracellular effects; that is, no unitary theory of intracellular and 
extracellular S100B effects can be currently predicted. 
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1.1.1. Intracellular functions of S100B in the Central Nervous System 
It is now known that within CNS S100B is mostly expressed by astrocytes and 
some oligodendrocytes (OL) of hippocampus and brain cortex, although it can also be 
present in certain neuronal subpopulations (Gerlach et al., 2006; Hachem et al., 2005; 
Steiner et al., 2007). The greatest amount of S100B is located within the cytoplasm, 
with only about 7% bound to the membranes. S100B involvement in cellular events has 
been extensively studied and includes the regulation of cell proliferation and 
differentiation, as well as the control of the assembly of cytoskeleton components, 
intracellular Ca2+ homeostasis and proteins activities, interactions and modifications 
(Figure I. 1) (Donato et al., 2009).  
Figure I. 1 – Schematic representation of S100B intracellular effects in central nervous 
system cells.  
It is known that S100B interacts with cytoskeleton components, modulating their 
assembly and disassembly (Garbuglia et al., 1998; Sorci et al., 1998). Indeed, recent 
data have shown that S100B is involved in astrocytic migratory ability and star-shaped 
morphology by regulating the molecular organization of actin filaments (F-actin) in a 
PI3-K dependent manner. PI3-K regulates then Akt(PKB)/GSK3β/Rac1 and small 
GTPase RhoA/ROCK pathways, both involved in the formation of stress fibers 
S100B
Neurons Astrocytes
MicrogliaOligodendrocytes
Star-shaped morphplogy
Migration
Proliferation
Diferentiation
Migration Migration
Phagocytosis
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promoting the creation of cytoplasmic extensions and favoyring cell locomotion  (Brozzi 
et al., 2009; Watanabe et al., 2004). In addition, S100B was found to be associated 
with microtubule-like structures and centrosomes on microglia, suggesting its 
involvement on activation and phagocytic ability characteristics of these glial cells 
(Adami et al., 2001).  
S100B was shown to play an important role in the regulation of neuronal 
proliferation and differentiation during early development stages. The overexpression of 
S100B in the neuronal cell line pheochromacytoma PC12 exposed to the neurotrophin 
nerve growth factor (NGF) has been demonstrated to enhance cell proliferation and 
reduce differentiation through activation of Akt/p21WAF1/cyclin D1-cdk4/Rb/E2F pathway 
(Arcuri et al., 2005). It has also been shown that S100B is involved in the regulation of 
astrocytes proliferation and differentiation, trough activation of PI3-K in a Src kinase-
dependent manner (Brozzi et al., 2009). Experiments in mouse cerebellar cultures 
have demonstrated that S100B plays a role in the maintenance of Ca2+ homeostasis in 
astrocytes which in turn are important in the regulation of neurophysiology and in the 
modulation of neuronal activity (Agulhon et al., 2008; Xiong et al., 2000).  
Moreover, recent data regarding oligodendroglial cells revealed the presence of an 
expression pattern of S100B along their differentiation and maturation (Figure I. 2) 
(Deloulme et al., 2004). Mature myelinating OL are known to descend from a pool of 
multipotent precursor cells maintained in specific regions of the CNS. These precursor 
cells undergo several changes at morphological and antigenic markers expression 
levels, until becoming myelinating OL, being described four transitional cell stages: OL 
precursor cells (OPC), preoligodendrocytes (or late OPC), immature (or pre-
myelinating) OL and mature (or myelinating) OL (Dawson et al., 2000; Levine et al., 
2001).  
Particularly, S100B is mostly expressed in these intermediate cell stages, 
suggesting its enrolment in OPC proliferation and differentiation into mature OL. Also, 
S100B expression was shown to greatly increase during the transition between non-
myelinating pre-OL and mature OL, which might be explained by the fact that 
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cytoplasmic S100B is associated with cytoskeleton components, such as microtubules, 
present in the extensions and membranous sheaths developed by maturing OL 
(Deloulme et al., 2004; Zhang, 2001).  
Figure I. 2 – Schematic representation of S100B and other markers expression along OL 
lineage development. OPC, oligodendrocyte precursor cells; OL, oligodendrocyte; NG2, 
chondroitin sulphate proteoglycan; MBP, myelin basic protein; PLP, proteolipid protein, 
(Adapted from Deloulme et al., 2004; S. C. Zhang, 2001) 
All this regulation events carried out by S100B makes evident its importance along 
the CNS development, as well as in the course of brain insults when astrocytes and 
microglia become activated and, together with OPC, migrate to areas of insult in an 
effort to restore its proper performance (Zlokovic, 2008). 
1.1.2. Extracellular functions of S100B in the Central Nervous System 
As previously mentioned, within CNS S100B is mainly secreted by astrocytes in a 
constitutive manner (Shashoua et al., 1984). Secretion of S100B has been shown to be 
regulated by a number of external factors and condition, some of them augment it 
others repress it. Indeed, tumor necrosis factor- (TNF-α), interleukin-1β (IL-1β), 
serotonin, lysophosphatidic acid, low levels of glutamate, low extracellular Ca2+ levels, 
metabolic stress and serum deprivation are known to enhance S100B release. On the 
other hand, factors as elevated levels of glutamate and glucose, inhibition of Src kinase 
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activity, cell confluence, Ca2+ channel blockade and gap junction inhibition are known 
to reduce S100B secretion (Sorci et al., 2010).  
Interestingly, depending on the concentration present in the extracellular space, 
S100B is known to act as a neurotrophic or neurotoxic molecule (Figure I. 3). Indeed, 
under physiological conditions, S100B levels in the brain extracellular space range 
around a few nM concentrations. At this concentration S100B is known to exert trophic 
effects on neurons, stimulating neurite outgrowth and increasing neuronal survival 
during development and following injury via stimulation of extracellular signal-regulated 
kinases (ERK) 1 and 2 ad of the nuclear factor-B (NF-B) as well as up-regulation of 
the anti-apoptotic protein Bcl-2 (Barger et al., 1995; Businaro et al., 2006; Huttunen et 
al., 2000). Still, under stress conditions S100B tends to be secreted in higher amounts, 
reaching concentrations on the order of M, at which S100B exerts neurotoxic effects 
via overproduction of reactive oxygen species and activation of apoptotic pathways 
(Donato et al., 2009).  
As described above, both trophic and toxic effects of extracellular S100B are 
mediated in the brain by binding to the receptor RAGE (Donato, 2007; Leclerc et al., 
2009). RAGE is expressed in several cell types, including neurons, and its ligation by 
S100B on these cells has been shown to be someway responsible for the protein dual 
roles (Sorci et al., 2013). Low S100B doses protect neuronal cells from β-amyloid 
toxicity and also activates anti-apoptotic pathways via RAGE engagement. In contrast, 
an excessive stimulation of RAGE as consequence of S100B binding results in the 
hyper-activation of the pro-apoptotic Ras/MEK/ERK pathway and subsequent 
overproduction of reactive oxygen species (Businaro et al., 2006; Huttunen et al., 
2000). Nevertheless, opposite outcomes resultant from S100B/RAGE interaction might 
depend on the number of RAGE molecules available on the cell surface. Moreover, 
since only high levels of S100B are able to promote RAGE dimerization consequent 
activation of pro-inflammatory cells, it is possible that, under low levels of S100B, 
RAGE may recruit other factors to different intracellular signaling pathways (Sorci et al., 
2010, 2013).   
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Figure I. 3 – Schematic representation of S100B extracellular effects on central nervous 
system cells. At nanomolar concentrations S100B exerts a beneficial effect on CNS cells (A), 
whether higher concentrations are detrimental, favoring a pro-inflammatory scenery (B). 
Besides neurons, extracellular S100B also affects surrounding glial cells, mainly 
astrocytes and microglia, in a concentration-dependent manner (Nardin et al., 2007). 
S100B acts on astrocytes in an autocrine way, and at nM levels stimulates their 
proliferation by phosphorylation of ERK1/2 (Gonçalves et al., 2000; Selinfreund et al., 
1991). This astrogliosis is counteracted by elevated concentrations of S100B, that 
stimulate inducible nitric oxide synthase (iNOS) activity, via activation of NF-κB and 
nitric oxide (NO), once synthesized leads to astrocyte apoptosis (Lam et al., 2001; 
Petrova et al., 2000). Similarly, high S100B stimulates IL-1β, interleukin-6 (IL-6) and 
TNF-α release from astrocytes, meaning that S100B is likely to take part on activation 
of brain inflammatory response (Hu and Van Eldik, 1999). Controversially, high S100B 
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levels might be beneficial in the course of brain inflammatory processes, once by 
inducing apoptosis might contribute to the reduction of activated astrocytes which in 
turn might attenuate inflammatory response.  
Extracellular S100B also affect microglia, the brain resident macrophages (Adami 
et al., 2001). At physiological levels, S100B has the effect to prevent microglia 
activation via STAT3 pathway (Zhang et al., 2011b). By contrast, µM concentrations of 
S100B synergistically with cofactors like bacterial endotoxin or interferon-γ (IFN- γ) are 
known to mediate microglia activation. This activation occurs via stimulation of iNOS 
and consequent enhance of NO release, being crucial to trigger brain inflammatory 
response (Adami et al., 2001; Petrova et al., 2000). Some effects of S100B on both 
astrocytes and microglia also seem to be mediated by RAGE ligation (Ponath et al., 
2007; Sorci et al., 2013). Thus, extracellular S100B is now being used as a parameter 
of glial activation or commitment in several situations of brain injury.  
S100B expression and release was thought to be restricted to astrocytes for 
decades. However recent data has demonstrated that mature OL from the OL-93 cell 
line also secrete S100B at a higher level than astrocytes under serum and glucose 
deprivation conditions (Steiner et al., 2008a). Consequently, such high concentrations 
of S100B might be detrimental for both OL proper function and OPC differentiation into 
myelinating OL. In this regard, our group observed that exposure of OPC to 
pathological concentrations of S100B (1µM) decrease OPC differentiation when 
compared to OPC treated with control or S100B physiological levels (10 nM), impairing 
therefore their ability to became myelinating cells (Figure I. 4; unpublished data). These 
results suggest a possible enrolment of S100B in myelination.  
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Figure I. 4 – Extracellular effects of different S100B concentrations upon oligodendrocyte 
precursor cells (OPC) development. Only low doses of S100B reduce the number of myelin 
basic protein (MBP)+ cells (red), slightly increasing the number of NG2+ immature ones (green). 
(Adapted from Santos G PhD work). 
1.2. S100B as a biomarker of brain damage 
There are several studies that reveal an association between elevated levels of 
S100B and CNS disorders, based both on S100B detection on body fluids for post-
mortem specimens. Augmented S100B levels were first detected in cerebrospinal fluid 
(CSF) of multiple sclerosis (MS) patients in the acute phase (Michetti et al., 1979). 
Since then, studies of S100B detrimental effects were extended to other diseases of 
the CNS. High levels of S100B have been detected in a number of brain-related 
diseases such as Alzheimer disease, Down syndrome, amyotrophic lateral sclerosis 
and Parkinson disease (Harpio and Einarsson, 2004; Shakeri et al., 2012; Steiner et 
al., 2011; Uher and Bob, 2012).  
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Actually, due to high levels of S100B expression in the brain and because it is 
released from injured astroglial and/or OL cells in the course of an insult, S100B is 
increasingly being considered as a biomarker for brain damage (Shakeri et al., 2012; 
Sun and Feng, 2013). Indeed, S100B has already been identified as a potential 
biomarker in cases of premature and traumatic brain injury, once it has been reported 
to be augmented in the CSF and serum of patients following such traumas (Beharier et 
al., 2013; Kleindienst and Ross Bullock, 2006). 
Moreover, the fact that some of the detrimental effects resulting from 
overexpression of S100B are mediated trough RAGE engagement and that both 
astrocytes and microglia express this receptor, suggest a possible involvement of 
S100B/RAGE interaction in the course of some neurodegenerative disorders (Bianchi 
et al., 2011; Donato et al., 2009; Ponath et al., 2007). In fact, recent data from a human 
neuroblastoma cell line (LAN-5) suggest that while nM levels of S100B counteract 
amyloid-β (Aβ) peptide neurotoxic effects in a RAGE dependent manner, µM levels 
S100B exacerbates Aβ toxicity (Businaro et al., 2006).  
Overall, given the importance of S100B in the regulation of several events within 
CNS cells as well as its implication in some neurodegenerative diseases, it is of great 
interest to explore its possible role in other brain damage related pathologies.  
 
 Demyelinating Disorders 
A demyelinating disease consists of total or partial loss of the myelin sheath that 
surrounds axons, compromising their proper function and integrity. This loss occurs in 
response to intrinsic or external factors, such as inflammatory processes, metabolic 
derangements, hypoxia-ischemia and viral infections, that might target either the own 
myelin or the cells that synthesize it – OL in the CNS or Schwann cells in the peripheral 
nervous system (PNS) (Love, 2006; Mayo et al., 2012). Usually, following 
demyelination spontaneous remyelination might occur allowing a partial recovery, and 
it is the balance between demyelination and remyelination that defines the outcome of 
the disease (Franklin and Ffrench-Constant, 2008).  
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CNS demyelinating disorders include MS, Marburg disease, neuromyelitisoptica 
(NMO), Balo’s concentric sclerosis, acute disseminated encephalomyelitis (ADEM) and 
acute hemorrhagic leukoencephalitis (AHL) (Bunyan et al., 2012; Popescu and 
Lucchinetti, 2012). Since MS is the most prevalent demyelinating disorder among 
young adults we focused our study is this disorder.  
2.1. Multiple Sclerosis as the most common demyelinating disease 
MS is the major demyelinating disease of the CNS, occurring in an inflammatory 
background. MS is considered to be the most common cause of non-traumatic 
disability in young adults, with a great socio-economic impact worldwide, with each 
individual costing about €2 million during his lifetime. Most recent data show that there 
are about 2.5 million people with MS worldwide, with an incidence of 2.5 per 100 000, 
and a higher prevalence in developed regions (e.g. Europe with 80/100 000) than in 
underdeveloped countries (e.g. Africa with 0,3/100 000) (WHO, 2008). In Portugal, 
accordingly to the most recent studies there is an estimated prevalence of 56,2 per 
100 000, i.e., there are 5620 MS patients per 10 million inhabitants, of which only about 
3500 to 4000 are known to receive directed therapy for the disease (de Sá et al., 
2012). 
MS is characterized by the occurrence of areas of acute focal inflammatory 
demyelination, variable gliosis and relative axonal loss with limited remyelination, 
culminating in the formation of chronic multifocal sclerotic plaques. These lesions occur 
preferentially in optic nerves, subpial spinal cord, brainstem, cerebellum, and 
periventricular white matter regions (Compston and Coles, 2008; Love, 2006). MS 
pathogenesis is not fully understood and even though it is subject of controversy, there 
are strong evidence for an autoimmune pattern with auto-reactive immune cells 
crossing the blood-brain barrier to attack myelin and axons (Brassat, 2012; Corthals, 
2011). 
The onset of MS occurs between 15 and 55 years and is two to three times more 
frequently in women than men. MS etiology is unknown, though several studies for the 
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past few years have shown that it results from the interaction of diverse risk factors 
such as: genetic susceptibility (MHC class II-associated HLA-DRB1*15, ethnic origin 
and sex), viral infection (EpsteinBarr virus), behavior (smoking) and environment 
(latitude and lack of vitamin D) (Ramagopalan et al., 2010). Symptomatically, MS is 
characterized by the occurrence of motor weakness, vision loss, diplopia, ataxia, 
cognitive impairment, bowel and bladder dysfunction and cortical dysfunctions such as 
seizures (Compston and Coles, 2008; Milo and Miller, 2014).  
 
2.1.1. MS clinical course 
MS clinical course has been categorized in four types, accordingly to the 
emergence of disabilities (Figure I. 5). Most frequently, MS disease starts with a course 
of demyelination insults followed by periods of neurological recovery, being designated 
relapsing-remitting MS (RRMS). This revisable disability is characterized by focal areas 
of inflammatory demyelination in which myelin, OL and axons become damaged 
(Hanafy and Sloane, 2011; Peterson and Fujinami, 2007). Relapses are associated 
with the reactivation of old lesions or even with the appearance of new ones, while 
remittance periods are the result of the resolution of inflammation and remyelination 
(Chandran et al., 2008; Compston and Coles, 2008). The time elapsed between 
relapses is variable, with the latent phase between the first manifestation of MS and the 
first relapse going from little months to several years. With the recurrence of relapsing 
and remittance episodes, recovery from each episode tends to be incomplete with 
consequent accumulation of persistent symptoms (Compston and Coles, 2008; Trapp 
and Nave, 2008). 
RRMS stage is normally followed by a phase of uninterrupted disease progression, 
determined as secondary progressive MS (SPMS). This phase is characterized by a 
continuous and irreversible neurological degeneration, as there is no remyelination and 
subsequently no axonal regeneration (Vukusic and Confavreux, 2003). A small 
percentage of MS patients (10-15%) doesn’t pass by the relapsing-remitting phase, but 
instead experiment an uninterrupted disease progression from the beginning, being 
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referred as primary progressive MS (PPMS). The rarest type of MS is progressive-
relapsing MS (PRMS) characterized by a progressive onset interspersed by acute 
relapses, with or without recovery, and a continuous progression in the period between 
the relapses. PRMS may represent a rare subtype of PPMS since both present a 
similar history (Lim et al., 2004; Wolinsky, 2003). 
Figure I. 5 – Schematic illustration of how of disability evolves through time in MS. 
Progressive forms of MS are the most troublesome, not only because patients 
become disabled due to fail of remyelination but also because there is no successful 
therapeutic at the time to combat physical, cognitive, and quality of life deterioration 
that these MS patients have to face. Thus, it is imperative to research and develop 
novel therapies in this direction.  
2.1.2. MS pathophysiology 
The main hallmark of MS is the loss of myelin. The main function of myelin sheaths 
is to enable saltatory conduction of impulses, playing a dynamic and vital role on the 
I. Introduction 
16 
 
maintenance of axonal homeostasis and integrity (Compston and Coles, 2008; 
Griffiths, 1998). Within the CNS, myelin is synthesized by mature OL that emit 
processes from their own cytoplasmic membranes and continuously envelop axons, 
forming a multilamellar compacted membrane (Deber and Reynolds, 1991). As 
extensions of cytoplasmic membranes, myelin sheaths consist on a proteolipidic 
foundation and are constituted by two major proteins: proteolipid protein (PLP) and 
myelin basic protein (MBP). Unlike PNS, where each myelin sheath is produced by a 
single Schwann cell, in the CNS OL are able to furnish about 40 or more adjacent 
axons, influencing axonal caliber and improving their integrity and stability (Tzakos et 
al., 2005; Witt and Brady, 2000). 
Although immune-mediate theory of MS pathology is not the only under 
discussion, it is the one that is most described and has been target of extensive 
research (Corthals, 2011; Nakahara et al., 2012). In this context, the loss of myelin 
sheaths occurs as consequence of the migration across the blood brain barrier of auto-
reactive T-lymphocytes against myelin components. These activated T-cells will be 
induced to differentiate in lymphocytes T helper CD4+ (ThCD4+) which in turn will be 
reactivated by MHC-II-expressing macrophages or dendritic cells that present myelin 
elements (Figure I. 6) (Mayo et al., 2012).  
In turn, reactivated T-cells circulate within the CNS and together with activated 
macrophages, microglia and astrocytes secrete soluble factors like pro-inflammatory 
cytokines and chemokines, such as IFN-, TNF-, high motility group box 1 (HMGB1) 
and matrix metalloproteinases (MMPs) (Amor et al., 2010; Van der Walt et al., 2010). 
The accumulation of these pro-inflammatory factors as well as the cells that produce 
them leads to the recruitment of naïve microglia and consequent activation, amplifying 
the inflammatory and immune response that culminates with demyelination (Lassmann 
and van Horssen, 2011; Nakahara et al., 2012).  
A growing body of evidence strongly suggests the involvement of inflammasomes 
in the regulation of inflammatory response that leads to demyelination. NLRP3, a 
member of the nucleotide-binding domain, leucine-rich repeat containing (NLR) family, 
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is pyrin-domain containing 3, is a core component of the inflamasome complex 
(Lequerré et al., 2007; Sutterwala et al., 2006). Moreover, NLRP3 has been suggested 
to be implicated in neuroinflammation and demyelination events in an in vivo model of 
MS trough interleukin-18 (IL-18). The same study has revealed that IL-18, one of the 
end products of the inflammasome, exacerbates demyelination and inflammatory 
outcomes, such as astrocytic and microglia activation (Jha et al., 2010).  
Figure I. 6 – Schematic representation of MS pathophysiology mechanisms. Autoreactive 
T CD4+ cells are activated in the periphery, transmigrate trough the blood-brain barrier (BBB) 
into the central nervous system (CNS), and are locally reactivated by antigen presenting cells 
(APS). Activated T CD4+ cells secrete pro-inflammatory cytokines and, together with other 
successively recruited and activated immune cells, such as T CD8+ and B cells, create a pro-
inflammatory environment, leading to myelin, oligodendrocyte (OL) and axon damage, with 
consequent neurologic dysfunction. MBP, myelin basic protein; PLP, proteolipid protein; Tc, T 
cytotoxic lymphocytes; Th, T helper lymphocytes; APC, antigen presenting cell; IL-18, 
interleukin-18; IFN-, interferon-; TNF-, tumor necrosis factor ; HMGB1, high motility group 
box 1; MMP, matrix metalloproteinase.  
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Another important factor in the potentiation of inflammation is HMGB1, which 
within the CNS can be secreted by astrocytes, microglia and neurons (Andersson et 
al., 2000). HMGB1 triggers inflammatory response mainly through binding to RAGE, 
the same receptor by which extracellular S100B operates (Kokkola et al., 2005). 
Recent studies have shown an exacerbated expression of both HMGB1 its receptor 
RAGE and in MS lesions, suggesting a potential interaction of these molecules in the 
inflammatory process involved in MS pathogenesis (Andersson et al., 2008). 
Following demyelination myelin debris are phagocytized by local macrophages, 
differentiated from monocytes that cross the blood-brain barrier (BBB), and from 
resident microglia. Additionally, astrocytes and microglia secrete neurotrophic 
molecules that mediate the recruitment of OPC to the freshly demyelinated focuses. 
Once in MS lesions, OPC are induced to proliferate and differentiate into pre-OL, pre-
myelinating OL, and then mature myelinating OL. These cells will then regenerate 
myelin sheaths, restoring axonal conduction in some way (Miron et al., 2011). This, 
remyelination, is as effective as sooner migration of OPC occurs, i.e., it has been 
shown that remyelination might not succeed in case of a late migration of OPC or 
failure to differentiate. With the progression of the disease and the exposure to 
repeatedly demyelinating insults, OPC pool undergoes exhausted and remyelination 
also tends to fail (Chandran et al., 2008; Franklin and Ffrench-Constant, 2008; Patel 
and Klein, 2011).  
 
2.2. S100B in Multiple Sclerosis 
As mentioned above, MS pursues a path of neuroinflammation, glial reactivity and 
oligodendropathy. Similarly, S100B has been shown to be involved in the previous 
events in some way. In fact, it has been shown the presence of S100B in acute lesions 
of post-mortem brain tissue of MS patients in the relapsing remitting stage, allowing to 
distinguish between this and the progressive phases (Petzold et al., 2002). In line with 
these results, our group, in collaboration with Jack van Horssen (VU University, 
Amsterdam, The Netherland) demonstrated that S100B is overexpressed both in active 
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and chronic lesions mainly by astrocytes. While in active lesions S100B surrounds the 
demyelinated area, in chronic ones S100B is diffusely expressed within the 
demyelinated areas. Expression of S100B receptor RAGE was also shown to be 
exacerbated in active MS lesions, being expressed by macrophages/microglia.  
S100B was also shown to be increased in CSF and serum of MS patients in both 
RRMS and progressive stages, levels that significantly decreased after therapy with an 
immunosuppressive agent (Bartosik-Psujek et al., 2011; Petzold et al., 2002). 
Accordingly, recent data from ongoing work of our group in collaboration with João 
Cerqueira (ICVS, Univ. Minho) demonstrated that in CSF samples from RRMS patients 
there is a significant increase of S100B production at the time of diagnosis. These 
results suggest that S100B might be a potential biomarker for MS diagnosis and 
prognosis allowing the distinction of different MS stages. On this background we 
hypothesize that S100B might play a role in the course of demyelination and 
remyelination events regarding MS.  
Experimental Demyelinating Models 
The lack of an effective therapy for the treatment of MS to date as well as the 
unknown of its correct pathophysiology led to the development of experimental models 
that mimic both the symptoms and the hallmarks of the disease. Rodents, such as rat 
and mice, have been a preferential target to develop human disease models, as they 
are easy to manipulate but also because of their relative genetically closeness to 
humans (Craig et al., 2003). The heterogeneity of MS causes it to be difficult to 
represent, leading to the development new models that allow the study of mechanisms 
of the disease towards its treatment (Murta and Ferrari, 2013).  
3.1. In vivo Animal Models 
One of the most widely applied models in MS research is experimental 
autoimmune encephalomyelitis (EAE). This model was developed in the late 20s as an 
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effort to understand neuroparalytic accidents, a complication of vaccination against 
rabies virus. Animals, initially non-human primates, were injected with brain tissue 
homogenates containing adjuvants, similarly to what was being used for rabies 
vaccination, and it was observed the occurrence of allergic encephalitis in result of 
such inoculations. Experiments were extended to other animals such as pigs, dogs, 
rats and mice and soon it was found a resemblance between EAE and MS 
histopathology (Croxford et al., 2011; Jervis, 1954; Waksman and Adams, 1962). 
Currently, EAE is mostly produced in C57BL/6 mice with the disease being induced by: 
(i) inoculation with myelin oligodendroglial glycoprotein (MOG) emulsified in an 
immunopotentiator solution (Freund’s adjuvant supplemented with Mycobacterium 
tuberculosis); and (ii) and injection of pertussis toxin on the day of immunization and 2 
days thereafter, which will stimulate cell-mediate immune response (Paterson, 1979). 
Although it has been demonstrated that EAE model plays a key role in the 
understanding of autoimmunity, neuroinflammation, cytokine biology and 
immunogenetics of MS, it presents some limitations (Waksman, 1999). In fact, EAE 
does not reproduce relapses which difficults the study of remyelination. There are still 
some differences between EAE and MS, such as the regions of the CNS that are 
mostly affected (spinal cord white matter and cerebral for EAE and cerebellar cortex for 
MS) and the cells of the innate immune response that are mostly activated (CD4+ for 
EAE and CD8+ T cells for MS) (Ransohoff, 2012; Saxena et al., 2011).  
In order to fulfill some gaps presented by EAE model such as the lack of 
remyelination, an important hallmark of RRMS, there was a need to develop other 
models. An alternative in vivo model that showed to reproduce MS pathology was the 
administration of neurotoxins (Rodriguez, 2007). One of the most common toxin used 
is the copper chelator cuprizone that is fed with chow preferentially to vulnerable 
strains of animals (mice, rats) during 4-6 weeks, after which extensive remyelination 
ensues. Pathologically, cuprizone has demonstrated to cause mitochondrial 
dysfunction and to be selectively toxic to mature OL (Komoly et al., 1987; Venturini, 
1973). One of the main advantages of cuprizone toxic model is the resemblance of 
demyelination and remyelination lesions to those occurring in MS patients, allowing a 
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closer insight into the disease itself and the expansion of treatment options for the 
patients (Denic et al., 2011; Ransohoff, 2012).  
3.2. Ex vivo Organotypic Slice Cultures 
In vivo models represent an expensive cost, both economically and ethically; thus, 
alternatives should be preferentially used whenever possible. Organotypic slice 
cultures have been used for decades in diverse CNS research fields, including 
electrophysiology and drug screening, mainly due to the maintenance of the three-
dimensional architecture that held the tissues together allowing cell-cell interactions, 
and to their long-term survival in culture (Gähwiler, 1988; Stoppini et al., 1991).  
Regarding MS, cerebellar organotypic slice cultures (COSC) have been shown to 
mimic demyelination and inflammatory processes when exposed to the toxin 
lysolecithin or lysophosphatidylcholine (LPC) (Allt et al., 1988). This toxin was primarily 
used to induce demyelination in a mice in vivo model by sub-perineurial injection on 
mature myelinated peripheral nerve fibers. Demyelination capacity was proposed to 
occur due to toxic detergent effects of LPC on myelin sheath (Hall and Gregson, 1971). 
Also, LPC-induced demyelination is thought to occur through the recruitment of 
macrophages and microglia which phagocyte the nearby myelin (Munder and Modolell, 
1979). 
The strength of this model when compared to in vitro models (i.e. cultures of OL 
and OPC), is the presence of the other glial cells, microglia and astrocytes, and 
neurons. This presence is a key factor as axons are needed for myelin ensheathment 
by OL, and also because astrocytes and microglia secrete factors that might promote 
or prevent myelination, accordingly to the surrounding environment (Dean et al., 2011; 
Schnädelbach et al., 2001). Moreover, the fact that the three-dimensional cell structure 
is relatively preserved is an essential aid for the occurrence of these events, as 
relationships among the different cell types are maintained (Avossa et al., 2003; 
Ghoumari et al., 2003). Furthermore, cerebellum is preferentially used in research 
studies regarding MS rather than other CNS regions, such as the spinal cord and the 
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brain stem, due to the abundance of white matter. Also, when submitted to LPC toxic 
stimulus, cerebellum requires less 2 hours of incubation than spinal cord and brain 
stem, which together allow a clearer perception of the lesions and to obtain faster 
results (Zhang et al., 2011a). 
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Aims 
The main purpose of this work is to assess whether S100B is expressed in the 
course of a demyelinating insult and in what way its expression affects demyelination 
and remyelination, as well as reactivity of glial cells. For this, we will use a COSC from 
wild-type (WT) CD1 mice as model and induce demyelination insults using LPC.  
In a first approach we will keep COSC for 7 days in culture, at which demyelination 
will be induced. COSC will then be maintained in culture for more 48 hours after the 
insult. At this point, we will determine S100B gene expression and release to the 
extracellular space, and which cells are producing it.  
At a second approach we will incubate COSC with an anti-S100B antibody that will 
block S100B protein, in order to assess whether S100B is affecting demyelination and 
in what extent. We will also evaluate the reactivity of glial cells in response to the 
demyelinating insult, and in what way S100B might be involved in their activation.  
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. Material and Methods 
Animals 
Pregnant CD1 mice were acquired from Instituto de Higiene e Medicina Tropical 
(IHMT, Lisboa, Portugal). Animals were supplied with standard laboratory chow and 
water ad libitum. Animal care followed the recommendations of European Convention 
for the Protection of Vertebrate Animals Used for Experimental and Other Scientific 
Purposes (Council Directive 86/609/EEC) and National Law 1005/92 (rules for 
protection of experimental animals). All animal procedures were approved by the 
Institutional Animal Care and Use Committee. All efforts were made to minimize animal 
suffering, to reduce the number of animals used, and to use alternatives to in vivo 
techniques. 
Organotypic Cerebellar Slice Cultures and Treatment 
Parasagittal slices were obtained from cerebellum of CD1 mouse pups at postnatal 
day 10 (Figure II. 1). In brief, brains were removed, cerebellum and attached hindbrain 
were isolated in phosphate buffered saline (PBS) and 400 µm slices were obtained 
using a Mcllwain tissue chopper and kept in an air-liquid interface system. Separated 
slices were placed in the upper chamber of a 0.4 μm pore cell culture (BD Falcon, 
#353493, Lincoln Park, NJ, USA) in a number of 4 slices per insert. Cell culture inserts 
were maintained in 6-well cell culture plates containing 1 mL of medium in the plate 
well at a 37ºC and 5% CO2 conditioned atmosphere. Slice culture media consisted of 
50% minimal essential media (MEM, Gibco, Life Technologies, Inc.,Grand Islands, 
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USA), 25% heat-inactivated horse serum (Gibco), 25% Earl’s balanced salt solution 
(Gibco), 6,5 mg/mL glucose, 25mM HEPES (Biochrom AG, Berlin, Germany) and 1% 
of both L-glutamine (Sigma-Aldrich, St. Louis, MO, USA) and penicillin/streptomycin 
(Sigma-Aldrich). After 3 DIV, slice culture media was totally replaced by a serum-free 
media consisting of 98% Neurobasal-A (Gibco) and 2% B-27 (Gibco), supplemented 
with 2 mM L-glutamine, 36 mM glucose, 1% U/mL penicillin/streptomycin and 25 mM 
HEPES. Half media was replaced every day and slices were maintained for 7 days in 
vitro (DIV) before treatment, to allow myelination and the clearance of debris 
(Birgbauer et al., 2004).  
 
Figure II. 1 – Schematic representation of COSC protocol. Cerebellum, separated from the 
brain of CD1 mouse pups at postnatal day 10, are sectioned into 400 µm thick slices. Separated 
slices are placed into the upper chamber of a cell culture insert and kept in an air-liquid interface 
system.  
Following the 7 days, COSC were exposed to a demyelinating insult with LPC (0,5 
mg/mL in serum-free culture media (Sigma-Aldrich). Following 16h LPC, COSC were 
transferred to serum-free media in which cultures were maintained up to 48h 
(Birgbauer et al., 2004; Miron et al., 2010). In parallel experiments, to ascertain S100B 
role on demyelination and glial reactivity, COSC were incubated with LPC in the  in the 
presence or absence of anti-S100B antibody (Figure II.2) (1:1000, #Z0311, Dako, 
Glostrup, Denmark). Supernatants were collected before and after LPC treatment. 
Slices were collected at 9 DIV (48h post-LPC), and either stored in TRIzol® reagent at 
-20ºC for RNA extraction or fixed in 4% paraformaldehyde (PFA) in PBS for 1h, rinsed 
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in PBS for 10 min twice and stored in PBS at 4ºC for immunohistochemistry assays.
Figure II. 2 – Schematic representation of culture treatment. 0h, 16h and 48h correspond to 
7 DIV, 8DIV and 9 DIV, respectively. LPC, lysophosphatidylcholine.  
Total RNA Extraction, Reverse Transcription and Semi-quantitative 
Real-Time Polymerase Chain Reaction 
In order to determine expression of S100B and other genes of interest, total 
cytoplasmic RNA was isolated from 9 DIV slices using the TRIzol® reagent method 
according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). RNA 
concentration was quantified using Nanodrop ND-100 Spectrophotometer (NanoDrop 
Technologies, Wilmington, DE, USA). Aliquots of 800 ng of total RNA were reversely 
transcribed using the Rivertaid H Minus First Strand cDNA Synthesis Kit (Thermo 
Fisher Scientific, MA, USA), under recommended conditions. qRT-PCR was performed 
on a real-time PCR detection system (Applied Biosystems 7300 Fast Real-time PCR 
System, Applied Biosystem, Madrid, Spain) using a SYBR Green qRT-PCR Master Mix 
(Thermo Fisher Scientific, MA, USA). The PCR was performed in 8-well strips with 
each sample performed in duplicate, and a non-template control (NTC) was included 
for each amplificate. The sequences used as primers are listed in the Table II. 1 
Table II. 1 – List of pairs of primers used for qRT-PCR assays. All primers were purchased 
from Thermo Fisher Scientific, MA, USA. 
Gene Sense Anti-Sense 
-actin gctccggcatgtgcaa aggatcttcatgaggtagt 
S100B gagagagggtgacaagcacaa ggccataaactcctggaagtc 
MBP ccatccaagaagaccccaca cccctgtcaccgctaaagaa 
PLP tggcgactacaagaccacca gacacacccgctccaaagaa 
HMGB1 ctcagagaggtggaagaccatgt gggatgtaggttttcatttctctttc 
IL-18 tggttccatgctttctggactcct ttcctgggccaagaggaagtg 
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qRT-PCR was performed under optimized conditions: 50ºC for 2 min, 95ºC for 10 
min followed by 40 cycles at 95ºC for 15 s and 62ºC for 1min. In order to verify the 
specificity of the amplification, a melt-curve analysis was performed, immediately after 
the amplification protocol (95ºC for 15 s, followed by 60ºC for 30s and 95ºC for 15s). 
Relative mRNA concentrations were calculated using the Pfaffl modification of the 
ΔΔCT equation, where CT is the cycle number at which fluorescence passes the 
threshold level of detection, taking into account the efficiencies of individual genes. The 
results were normalized to the housekeeping gene -actin in the same sample and the 
initial amount of the template of each trial was determined as relative expression by the 
formula 2-ΔΔCT. ΔCT is the value obtained for each sample by performing the difference 
between the mean CT value of each gene of interest and the mean CT value of -actin. 
ΔΔCT of one sample is the difference between its ΔCT value and the ΔCT of the sample 
chosen as reference.  
 
 Immunostaining procedure 
In order to determine the location of S100B expression as well myelination 
impairment, membranes containing the fixed slices were cut out from cell culture 
inserts, placed onto a slide and blocked in 1nM HEPES (Sigma-Aldrich), 2% heat-
inactivated horse serum, 10% heat-inactivated goat serum, 1% BSA (Sigma-Aldrich) 
and 0,25% Triton X100 (Roche Diagnostics, Indianapolis, USA) in Hank’s Balanced 
Salt Solution (HBSS, Gibco) for three hours, at room temperature. Slices were then 
incubated with (Table II. 2) primary antibodies diluted in the blocking solution, for 24h at 
4ºC. Following this, slices were washed three times for 15 min each with PBS with 
0.01% Triton X100 (PBS-T) before incubation with secondary antibodies (Table II. 3) in 
blocking solution for another 24 h at 4ºC). Slices were then washed three times for 15 
min each with PBS-T, incubated with DAPI (1:1000, 3 min), washed three times for 15 
min each with PBS-T and mounted using Fluoromount-G (Southern Biotech, 
Birmingham, AL) for confocal microscopy.  
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Percentage of the area immunoreactive for each antibody was measured from 8 
bit.lsm files of 512x512 pixel resolution images captured using a 20x/1.2(zoom) lens on 
a Confocal Point Scanning Microscope Zeiss LSM 510 META. Approximately, 4-5 
images were captured per slice per condition, thus reducing any variations in image 
acquisition. Binary masks were defined using a cut-off intensity threshold value, 
defined as the minimum intensity due to specific staining above background values. 
Then, the percentage of the area occupied by NF200, S100B, MBP, GFAP, NG2 and 
Iba-1 staining was measured automatically for each separated stack of every acquired 
image using ImageJ software. Regarding myelination, percentage of myelinated fibers 
was obtained by the ratio between the area of co-localization of NF-200 and MBP and 
the total area occupied by NF-200. Moreover, percentage of total area occupied by 
myelin was calculated by the average of MBP area of each co-staining (with NF-200, 
NG2, GFAP and Iba-1). Results are given by averaging values determined in the 
separate microscopic fields from slices of different animals. Values are expressed as 
mean ± SEM. 
Table II. 2 – List of primary antibodies used for immunoshistochemistry assays. 
Table II. 3 – List of secondary antibodies used for immunoshistochemistry assays. 
Antibody Host Brand Category Number Diluiton 
S100 Rabbit Dako Z0311 1:400 
NF-200 Mouse Novocastra NF200 1:200 
MBP Rat Serotec MCA409S 1:50 
GFAP Mouse Novocastra GFAP-GA5 1:100 
Iba-1 Rabbit Wako 019-19741 1:250 
NG2 Rabbit Milipore AB5320 1:50 
Antibody G Brand Category Number Diluiton 
Alexa 488 anti-mouse Goat Invitrogen A10680 1:1000 
Alexa 488 anti-rabbit  Goat Invitrogen A11008 1:1000 
Alexa 594 anti-rat  Donkey Invitrogen A21209 1:1000 
Alexa 594 anti-rabbit  Goat Invitrogen A11001 1:1000 
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 S100B assay 
Determination of S100B concentration released to the supernatants was 
performed by in house enzyme-linked immunosorbent assay (ELISA). Samples were 
incubated for 2 h at 37ºC on a 96 well plate (NUNC, Kamstrup, DK-4000 Roskilde, 
Denmark) previously coated with a monoclonal anti-S100B antibody (1:1000, #S2532, 
Sigma-Aldrich) 96-well plate previously coated with a monoclonal anti-S100B antibody 
(1:1000). Next, a polyclonal anti-S100B antibody (1:5000, Dako) was added and plate 
incubated for more 30 min at 37ºC. Finally, an anti-rabbit peroxidase-conjugated 
antibody (1:5000, #sc-2004, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was 
added for further 30 min at 37ºC. Colorimetric reaction with Sigma Fast OPD tablets® 
(Sigma-Aldrich) was measured at 492 nm in a BioRad microplate absorbance 
spectrophotometer.  
 
 Statistical Analysis  
All results are presented as mean ± SEM. Differences between two groups were 
determined by the two-tailed t-test performed on the basis of equal and unequal 
variance or by one-way ANOVA with Tukey post-test for multiple comparisons, using 
GraphPad PRISM 5.0 (GraphPad Software, San Diego, CA, USA), as appropriate. The 
P-values of P<0.05 and P<0.01 were considered as being statistically significant.  
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Results 
S100B is overexpressed and released from central nervous system 
cells following demyelination insult 
As previously mentioned, abnormal levels of S100B have been detected in the 
CSF and in post mortem plaques of MS patients (Bartosik-Psujek et al., 2011; Petzold 
et al., 2002). Thus, we wanted to attest weather S100B was being expressed in our 
model of demyelination. For this purpose, the levels of S100B protein released to the 
extracellular space were quantified in culture or incubation media collected before the 
incubation with LPC (0h), at 16h and 48h following the LPC stimulus by ELISA. As 
shown in Figure III. 1A, a marked increase in the release of S100B occurred at 16 h 
after LPC incubation (20.8-fold over control, P<0.001), which was maintained 48h 
following the LPC incubation (8.5-fold over control, P<0.001). 
Figure III. 1 – A demyelinating insult induces S100B production. Cerebellar organotypic 
slice cultures (COSC) were exposed to lysophosphatidylcholine (LPC) at 7 days in vitro (DIV) (0 
hours) for 16 hours. Samples for detection of S100B secretion were collected before the 
incubation (0h), at 16h and 48h following the incubation with LPC (A). Samples for analysis of 
mRNA expression were collected 48 after the LPC stimulus (B). Results are mean ± SEM. 
**P<0.01, ***P<0.001 vs Control.  
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In addition, we also measured the expression of S100B mRNA in COSC at 48h 
following LPC insult by qRT-PCR. Using primers specific to the S100B mouse gene we 
showed a significant increase of S100B expression in response to the demyelinating 
insult (3-fold over control, P<0.01) (Figure III. 1B).  
 
 S100B is mainly released by astrocytes during demyelination  
It is known that in the CNS S100B is expressed by most cells, and mainly secreted 
by astrocytes (Van Eldik and Zimmer, 1987). Knowing that S100B is being 
overexpressed and released to the extracellular space following the LPC insult, we 
wanted to assess which cells were generating such effect. For this end, we have 
compared the percentage of co-localization between S100B and neurons, astrocytes or 
OL. COSC fixed 48h following LPC insult were double immunostained with antibodies 
against S100B and one type of cell marker  NF-200, GFAP or MBP which allow the 
identification of neuronal axons, astrocytes and mature OL, respectively.  
As show in Figure III. 2, there is a major co-localization of S100B with GFAP 
(55.8%), even in control samples. Upon LPC treatment, co-localization of S100B with 
GFAP is still the most prevalent (37.5%), although we could observe a slight increase 
of S100B and MBP co-localization. These results allow us to assume that astrocytes 
are the major producers of S100B under demyelinating circumstances, although it is 
possible that mature OL may also be releasing S100B under this toxic condition, as 
previously documented (Steiner et al., 2008a).  
 
 Blockade of S100B partially attenuates demyelination induced by 
LPC  
Knowing that S100B is being overly secreted in response LPC-induced 
demyelination, we wanted to find out whether this increase in extracellular S100B could 
affect myelination related events. For this end, we evaluated the percentage of 
myelinated fibers in COSC at 48h post-LPC insult.  
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Figure III. 2 - S100B is mainly released from astrocytes upon demyelination. Cerebellar 
organotypic slice cultures (COSC) were exposed to lysophosphatidylcholine (LPC) at 7 days in 
vitro (DIV) (0 hours) for 16 hours. Immunostainings were performed in PFA fixed COSC 48 
hours post-LPC, with S100B, NF-200, GFAP and MBP antibodies (A). Quantification of the 
percentage of co-localization between S100B and neurons, astrocytes and OL was measured 
by the ratio between the area occupied by S100B and NF, GFAP or MBP staining and the area 
occupied by S100B staining (B). Scale bars represents 100 m. Results are mean ± SEM. 
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Slices were double immunostained with antibodies against both NF-200 and MBP, 
which allow the identification of neurofilaments and myelin sheaths, respectively. The 
percentage of myelinated fibers was calculated by the ratio of the area of co-
localization of NF-200 and MBP and the area occupied by NF-200. As depicted in the 
Figure III. 3, LPC stimulus effectively damaged myelin sheaths, which is corroborated 
by the decrease observed in MBP staining (0.8 -fold) and in myelinated fibers (0.6-fold, 
P<0.01). Interestingly, co-incubation with anti-S100B antibody partially decreased the 
demyelinating insult caused by LPC stimulus as observed by a reduced decreased in 
MBP staining (0.9-fold) and in myelinated fibers (0.8-fold) over control values.  (Figure 
III. 3A). The effect on myelinated fibers was significant, indicating that S100B inhibition 
may prevent demyelination.  
As previously mentioned, MBP and PLP are the main proteins constituents of 
myelin sheaths (Colman et al., 1982). As so, we decided to evaluate the expression of 
these proteins under demyelinating conditions caused by LPC incubation and how 
S100B could be affecting their expression. For this purpose, we measured the mRNA 
of MBP and PLP extracted from COSC 48h after LPC insult. The analysis of MBP and 
PLP mouse genes was performed by qRT-PCR with primers specific to the mouse 
genes. As illustrated in Figure III. 5, LPC insult promoted a significant increase in MBP 
and PLP expression (3.94-fold and 3.79-fold over control, respectively, P<0.01). 
Interestingly, co-incubation with anti-S100B antibody decreased the expression of both 
genes to a level close to the control expression (1.34-fold for MBP and 2.05-fold for 
PLP, over control). 
In general, demyelinating events are followed by spontaneous remyelination, 
which involves recruitment and proliferation of endogenous OPC into the injured area 
(Gensert and Goldman, 1997; Zhao et al., 2005). Thus, given the effective 
demyelination caused by LPC, we then aimed to explore whether remyelination was 
succeeding demyelination through the evaluation of the presence of OPC. For this 
purpose, COSC fixed 48h following LPC insult were double immunostained with 
antibodies against NG2, for OPC and against MBP for mature OL. 
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Figure III. 3 – Antibody directed blockade of S100B partially attenuates demyelination 
caused by LPC. Cerebellar organotypic slice cultures (COSC) were exposed to 
lysophosphatidylcholine (LPC) at 7 days in vitro (DIV) (0 hours) for 16 hours. Double 
imunostainings were performed in fixed COSC at 48h post-LPC with NF-200 and MBP 
antibodies (A). Area occupied with MBP staining was obtained by averaging the percentage of 
MBP area of each co-staining (B). Quantification of the percentage of myelinated fibers was 
calculated by the ratio between the area of co-localization of NF-200 and MBP and the total 
area occupied by NF-200 (C). Results are mean ± SEM. **P<0.01 vs control. ##P<0.01 vs LPC 
alone. Scale bar represents 100 m. 
The total area of OPC was calculated by averaging the percentage of area occupied by 
NG2 staining for each stack. As depicted in Figure III.5, LPC demyelination insult 
caused an increase in the number of NG2 positive cells (1.9 fold, P<0.05). Yet, co-
incubation with anti-S100B antibody showed to enhance this effect (3.0-fold, P<0.01), 
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while the addition of anti-S100B by itself can stimulate NG2+ cells proliferation. These 
data suggest that the presence of low levels of extracellular S100B, not bound to the 
anti-S100B antibody, might be exerting a recruiter and/or proliferative effect on OPC.  
 
Figure III. 4 – Blocking S100B decreases the expression of myelin genes following 
demyelination. Cerebellar organotypic slice cultures (COSC) were exposed to 
lysophosphatidylcholine (LPC) at 7 days in vitro (DIV) (0 hours) for 16 hours. Total mRNA was 
extracted from COSC at 48h post-LPC and gene expression was analyzed by qRT-PCR with 
primers specific to the MBP and PLP mouse genes. Results are mean ± SEM. **P<0.01 vs 
Control. ##P<0.01 vs LPC alone.  
 Abrogation of S100B decreases glial reactivity provoked by 
demyelation 
Along with myelin degeneration, demyelinating lesions are known to be succeeded 
by activation and proliferation of resident astrocytes and microglia (Dyer et al., 2005; 
Sofroniew and Vinters, 2010). Regarding this, and knowing that S100B is mainly 
secreted by astrocytes and is involved in the activation of both astrocyte and microglia, 
we decided to evaluate the degree of reactive gliosis in COSC in the course of the 
demyelinating insult with LPC, and what would be the potential role of S100B in such 
events.  
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Figure III. 5 – S100B abrogation causes an increase in OPC activation. Cerebellar 
organotypic slice cultures (COSC) were exposed to lysophosphatidylcholine (LPC) at 7 days in 
vitro (DIV) (0 hours) for 16h. Immunostainings were performed in fixed COSC at 48h post-LPC, 
with MBP and NG2 antibodies (A). Quantification of the area occupied by OPC was measured 
as the average of the area occupied by NG2 staining for each stack (B). Results are mean ± 
SEM. *P<0.05, **P<0.01 vs control; #P<0.05 vs LPC alone. Scale bar represents 100 m.  
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For this end, we evaluated the proportion of astrocytes and their morphology by 
double immunostaining of fixed COSC at 48h after LPC insult with antibodies for both 
MBP and GFAP, a well-established marker of astrogliosis. As shown in Figure III.6, 
LPC stimulus decreased the percentage of area occupied by astrocytes (0.4-fold, 
P<0.01 vs control), as a consequence of reduced extension number and length 
presented by activated cells. Interestingly, when COSC were co-incubated with anti-
S100B antibody we observed an increase in the percentage of the area occupied by 
astrocytes (1.2-fold vs control) to control levels, indicating a reduced activation state as 
evidenced by a more ramified morphology. 
Regarding microglia, we evaluated the proportion of microglia and their 
morphology by double immunostaining of fixed COSC at 48h following LPC insult with 
antibodies for both MBP and Iba-1, a commonly used marker for microgliosis. As 
shown in Figure III.7, incubation with LPC revealed to increase the percentage of Iba-1 
positive cells (2.0-fold, P<0.01). In turn, co-incubation with anti-S100B antibody in the 
presence of LPC maintained the levels of microglia found for LPC treatment (1.9-fold, 
P<0.01). Nevertheless, confocal imaging suggested that microglia position in slice 
could be altered. So, we explored the distribution of microglia along the slice, by 
normalizing the slice thickness for the amount of myelin and dividing into four equal 
percentiles. Indeed, the bottom and top of the slice were defined by the presence of 
MBP staining, the lowest stack showed reduced percentage of MBP area 
corresponding to the bottom of the slice (0) whereas the highest percentage 
corresponds to the top of the slice (1) (Figure III. 8B). Interestingly, we observed a 
growing percentage of the area occupied by Iba-1 staining along the slice, upon 
incubation with LPC, namely the bottom half. Co-incubation with anti-S100B did not 
prevent increased Iba-1 staining, but this increase was more evident in the upper half 
of the slice corresponding to the region with highest amount of myelin (Figure III. 8 
A,C). These data suggest that in the presence of low S100B (i.e. the amount free from 
anti-S100B binding) microglia presents a tendency to migrate into demyelinated 
lesions, possibly to increase the phagocytosis of myelin debris, a feature that is crucial 
for remyelination.   
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Figure III. 6 – S100B blocking prevents astrocytic activation triggered by demyelination. 
Cerebellar organotypic slice cultures (COSC) were exposed to lysophosphatidylcholine(LPC) at 
7 days in vitro (DIV) (0 hours) for 16h. Immunostainings were performed in fixed COSC at 48h 
post-LPC, with GFAP and MBP antibodies (A). Quantification of astrocytes was taken by 
averaging the area occupied by GFAP staining for each stack (B). Total mRNA was extracted 
from COSC 48h post incubation with LPC and the analysis of qRT-PCR products illustrated was 
conducted with primers specific to GFAP mouse gene (C). Results are mean ± SEM. **P<0.01 
vs control, ##P<0.01 vs LPC alone.. Scale bar represents 100 m. 
Altogether these results suggest that low levels of S100B might play a 
protective role under demyelinating conditions as it appears to revert astrocyte and 
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microglia activation, possibly attenuating the trigger of inflammatory response and 
creating an environment that favors remyelination.  
 
Figure III. 7 –S100B blocking partially attenuates microglia activation induced by LPC 
demyelination. Cerebellar organtypic slice cultures (COSC) were exposed to 
lysophosphatidylcholine (LPC) at 7 days in vitro (DIV) (0 hours) for 16h. Double 
immunostainings were performed in fixed COSC at 48h post-LPC, with Iba-1 and MBP 
antibodies (A). Quantification of microglia was taken by averaging the area occupied by Iba-1 
staining for each stack (B). Total mRNA was extracted from COSC 48h post incubation with 
LPC and the analysis of qRT-PCR products illustrated was conducted with primers specific to 
cd11b mouse gene (C). Results are mean ± SEM. **P<0.01 vs Control. Scale bar represents 
100 m.  
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Figure III. 8 – Blocking S100B apparently induces clearance of debris by microglia 
following demyelination. Cerebellar organtypic slice cultures (COSC) were exposed to 
lysophosphatidylcholine (LPC) at 7 days in vitro (DIV) (0 hours) for 16h. Double 
immunostainings were performed in fixed COSC at 48h post-LPC, with Iba-1 and MBP 
antibodies (A). Slice thickness was normalized for MBP staining, with 0 corresponding to the 
bottom of the slice (lowest MBP immunofluorescence) and 1 to the top of the slice (highest MBP 
immunofluorescence) (B). Normalized slice thickness was divided into four percentiles with the 
same relative thickness, and the area occupied by Iba-1 staining was analyzed for each 
percentile (C).  
 
 Inflammatory response triggered by demyelination is attenuated by 
S100B blockade 
Along with astrocytic and microglial activation, demyelination is also characterized 
by an exacerbated production of pro-inflammatory cytokines and chemokines 
(Sospedra and Martin, 2005). Since previous studies have shown that HMGB1 and IL-
18 are upregulated in MS patients (Andersson et al., 2008; Chen et al., 2012), we 
intended to evaluate the expression of these cytokines. For this end, we extracted total 
mRNA from COSC at 48h following LPC insult and HMGB1 and IL-18 mRNA 
expression was analyzed by qRT-PCR using specific primers. As shown in Figure III. 9, 
LPC insult promoted a marked increase in the expression of both genes (14.76-fold for 
HMGB1 and 10.87-fold for IL-18, over control).  
 
Figure III. 9 – S100B abrogation significantly decreases expression of pro-inflammatory 
cytokines HMGB1 and IL-18 elicited by demyelination. Cerebellar organotypic slice cultures 
(COSC) were exposed to lysophosphatidylcholine (LPC) at 7 days in vitro (DIV) (0 hours) for 
16h. Total mRNA was extracted from COSC 48h at post-LPC and HMGB1 and IL-18 mRNA 
expression was analyzes by qRT-PCR using primers specific to HMGB1 and IL-18 mouse 
genes. Results are mean ± SEM. Results are mean ± SEM. **P<0.01, ***P<0.001 vs Control. 
##P<0.01, ###P<0.001 vs LPC.   
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Additionally, when co-incubated with anti-S100B antibody, the expression of both 
HMGB1 and IL-18 significantly decreased to levels similar to control (1.95-fold for 
HMGB1 and 1.25-fold for IL-18, over control). These results clearly suggest that the by 
reducing S100B to physiological levels we might be somehow preventing the initiation 
of the inflammatory response.  
.
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Discussion 
S100B has currently been target of many studies related to neurodegenerative 
disorders. Indeed, abnormal levels of S100B expression have been detected in both 
CSF and post-mortem plaques of MS patients. The major hallmark of MS, an 
autoimmune demyelinating chronic disease of the CNS, is the formation of sclerotic 
plaques resultant from a process that involves reactive gliosis, inflammation, 
demyelination and remyelination, OL depletion, axonal loss and neuronal degeneration 
(Milo and Miller, 2014). Moreover, as previously mentioned, S100B has been described 
as being a mediator of inflammatory response in brain injury conditions (Donato et al., 
2009). 
With this work we intended to study the role of S100B in MS associated 
mechanisms, using a COSC model of demyelination (Birgbauer et al., 2004), 
addressing in particular demyelination and inflammation-related events. Even though 
abnormal levels of S100B have been detected in MS patients, there is no record of its 
direct involvement in demyelination mechanisms, so far. First of all, we evaluated both 
the production and expression of S100B in the course of the demyelinating insult with 
LPC. Our results revealed an overproduction and overexpression of S100B with a 
major co-localization with astrocytes, rather than neurons, and a slight co-localization 
with mature OL, detected by immunostaining directed to these cells (Figure III. 2). 
These data suggest that, in the model used in our work, astrocytes are the major 
producers of S100B in the course of demyelination. In fact, astrocytes are assumed as 
the CNS cell type with the highest expression rate of S100B and to constitutively 
secrete the protein (Donato, 2001; Van Eldik and Zimmer, 1987). In agreement, recent 
studies in rat COSC have shown an increase in astrocytes population 2 DIV after a 
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demyelination insult with LPC (Miron et al., 2010). The small co-localization with OL 
may suggest a reduced secretion of S100B by these cells when exposed to a toxic 
stimulus, as previously described for OL-93 cell line under serum and glucose 
deprivation conditions (Steiner et al., 2008b) 
Accordingly to previous reports, we observed that the concentration of LPC used 
as well as the length of the stimulus were effective in inducing demyelination, 
demonstrated by a reduction in the number of myelinated fibers (Figure III. 3) (Allt et 
al., 1988; Birgbauer et al., 2004). Interestingly, we observed that by adding an anti- 
S100B antibody to the incubation media in the presence of LPC, that can partially 
sequester the excessive release of S100, myelin sheaths damage was prevented. 
Additionally, the expression of the major proteins of myelin MPB and PLP was 
markedly enhanced following LPC injury. Previous studies on different in vivo models 
of demyelination have documented that the expression of MBP and PLP decrease 
immediately after the insult but undergo de novo synthesis afterwards, forecasting 
remyelination (Lindner et al., 2008; Woodruff and Franklin, 1999). These data appear 
to be in accordance with our results, since we observed a greater expression of MBP 
and PLP mRNA 30h after LPC incubation, relative to the control, suggesting an 
initiation of remyelination. Nevertheless, treatment with anti-S100B antibody abrogated 
MBP or PLP de novo synthesis when compared to LPC incubation.  
MBP and PLP de novo expression is necessary for remyelination (Lindner et al., 
2008; Zhang, 2001). Studies on COSC show that OPC differentiation and maturation 
as well as re-expression of myelin proteins occurs in a proportional temporal sequence 
than what would be observed in vivo (Birgbauer et al., 2004). As mentioned above, 
blockade of S100B is preventing extended demyelination by retrieving concentrations 
close to physiological. This way, it is possible that by no major need of remyelination, 
OL andde novo synthesis of myelin proteins might be reduced, as depicted in our 
results. In addition, we may not neglect the fact that MBP or PLP mRNA expression 
may be occurring at different time-points from the one-analyzed.  
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Remyelination requires activation of resident of OPC that will migrate to the injured 
area, proliferate and maturate into myelinating OL (Gensert and Goldman, 1997). The 
activation of OPC is characterized by a morphological change, where they assume a 
larger size and become more intensely labelled with NG2 (Kotter et al., 2001; Levine 
and Reynolds, 1999). Accordingly, our results reveal an increase in OPC activation 
following a transient demyelinating insult with LPC, shown by an augmented area of 
NG2+ cells.. Preliminary data from ongoing work in our group shows that pathological 
extracellular concentrations of S100B (1000 nM) affect oligodendroglial lineage 
development, specifically preventing differentiation of OPC, what may justify sich 
increase. Nevertheless, blocking of S100B in the media increased even more the levels 
of NG2+ OPC, suggesting a higher induction of the cells to a remyelinating event. It is 
known that S100 is necessary for OPC differentiation into mature OL (Deloulme et al., 
2004; Zhang, 2001). As so, it is possible that the presence of small levels of S100B 
that are not sequestered by the antibody may be promoting OPC proliferation for 
consequently differentiation and remyelination.given these data, additional studies 
should be performed for more extended periods of culture in order to analyze the 
remyelination potential of anti-S100B treatment.  
Reactive gliosis has long been associated with MS pathophysiology (Compston 
and Coles, 2008). Reactive astrocytes, which are implicated in formation of the glial 
scar, are characterized by dramatic morphological (cellular hypertrophy) and gene 
regulation (upregulation of GFAP) changes (Sofroniew and Vinters, 2010). Increased 
astrocytosis has also been observed during LPC induced demyelination in an COSC 
model (Miron et al., 2010). Our results show an increase of astrocytic activation upon 
LPC transient demyelination insult, evidenced by the reduction of cell extension lenght 
and inflated cell body. This activation was shown to be subsided with incubation of anti-
S100B. As previously discussed, astrocytes abundantly secrete S100B when exposed 
to the demyelinating agent. Moreover, excess of extracellular S100B levels induce 
autocrine astrocytic activation. In this situation, astrocytes secrete pro-inflammatory 
factors that can inhibit OPC proliferation and maturation, following demyelination in MS 
(Cammer and Zhang, 1999). Thus, the apparent absence of astrocytosis under 
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demyelinating conditions in the presence of anti-S100B, is a potential indicative that 
low levels of S100B might be preventing demyelination. Moreover, astrocytes in 
response to demyelination, under a non-inflammatory environment, are also 
responsible for the production of growth factors and chemokines that enhance OPC 
activation and consequently their migration and differentiation (Blakemore et al., 2003). 
As so, the reduced activation of astrocytes induced by anti-S100B antibody treatment 
may also corroborate the augmented number of NG2+ cells. 
Microglia activation in MS pathophysiology contributes to the creation of a pro-
inflammatory environment, by the secretion of pro-inflammatory factors, potentiating 
demyelination. Microglia activation has also been described in COSC models as 
consequence of demyelination (Birgbauer et al., 2004; Miron et al., 2010). Accordingly, 
our results reveal an increase in microglia proliferation and activation in the course of 
demyelinating insult, depicted by an augmented percentage of Iba-1 staining and 
apparent morphological change. Since S100B concentration on the range of M, as the 
ones measured in the present study, induce micoglia secretion of pro-inflammatory 
cytokines (Adami et al., 2001; Donato et al., 2009), it may be possible that S100B-
induced microglia activation exacerbates demyelination.  
On the other hand, our results showed that blocking of S100B did notmicroglia 
activation, although its presence shifted to myelin surrounds, as observed when 
different Z-stacks were analyzed (Figure III. 8). Microglia have an important role in the 
trigger of remyelination, as it promotes the clearance of myelin debris (Kotter et al., 
2001; Napoli and Neumann, 2010). In fact, there is a recent evidence that microglia 
switch from a cytotoxic to protector phenotype at remyelination initiation (Miron et al., 
2013). Moreover, extracellular S100B is known to inhibit microglia activation at 
physiological concentrations (Adami et al., 2001; Donato et al., 2009). As so, our 
results suggest that the low extracellular levels of S100B (i.e., not bound to anti-S100B 
antibody) under LPC plus anti-S100B treatment might be preventing microglia from 
acquiring a cytotoxic phenotype and promoting their phagocytosis and clearance of 
myelin debris, which will favor remyelination.  
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As previously referred, MS pathophysiology holds an inflammatory background. 
Particularly, activation of astrocytes and microglia in response to demyelination involve 
the secretion of several factors, such as pro-inflammatory cytokines. HMGB1, a 
cytokine involved in the initiation of inflammatory response within CNS, has recently 
been demonstrated to be upregulated in both acute MS lesions and rodent EAE lesions 
(Andersson et al., 2008). Moreover, IL-18, which also participates in the pathogenesis 
of autoimmune diseases as MS, has been shown to be increased in MS patients (Chen 
et al., 2012; Huang et al., 2004). In accordance, our results revealed a significant 
increase in the expression of both cytokines following LPC stimulus. interestingly, 
blockade of S100B showed to effectively revert the expression levels of these 
cytokines in a situation of demyelination. A recent report have pointed out that inhibition 
of IL-18 diminishes demyelination and promotes remyelination in a NLRP3 dependent 
manner (Jha et al., 2010). NLRP3, a member of the nucleotide-binding domain, 
leucine-rich repeat containing (NLR) family, pyrin-domain containing 3, is a core 
component of the inflamasome complex, and it has been proposed to be related to 
neuroinflammation and demyelination events (Sutterwala et al., 2006). Hence, it would 
be interesting to investigate the expression of NLRP3 in relation to S100B in our model 
of demyelination. In adition, since these cytokines as mainly expressed by activated 
microglia, their inhibition following S100B blocking corroborates microglia shift from a 
pro-inflammatory phenotype to a more neuroprotective one.  
Concluding Remarks 
With this work we demonstrated, in a COSC model, that LPC effectively induce 
demyelination and subsequent S100B overproduction. Moreover, the demyelinaton 
event led to the upregulation of myelin proteins and pro-inflammatory cytokines gene 
expression, as well as activation of astrocytes and microglia. In turn, blockade of 
pathological S100B levels appeared to prevent demyelination and promote increased 
remyelination, as well as to decrease both reactive gliosis and expression of pro-
inflammatory factors. Altogether, our results strongly suggest that S100B might be 
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directly involved in demyelination and remyelination mechanisms, in a concentration 
dependent manner. 
 
Figure IV. 1 – Schematic representation of main findings. (A) A situation of demyelination 
showed to induce secretion of S100B (mainly by astrocytes), microglia and astrocytes 
activation, and upregulation of pro-inflammatory cytokines. (B) Blocking S100B revealed to 
revert astrocyte activation and cytokine production, change microglia to a more neuroprotective 
role and to increase the number of OPC, as well.  
  
B
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